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https://doi.org/10.1016/j.xcrm.2020.100099SUMMARYRapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%–50% of nose/
throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the
D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect
anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid
antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-
type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI
57.8–92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected
by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.INTRODUCTION
As of August 2, 2020, >18.0 million people have been infected
with severe acute respiratory syndrome-coronavirus-2 (SARS-
CoV-2), with >690,000 deaths.1 The unprecedented numbers
requiring SARS-CoV-2 testing has strained healthcare systems
globally. There is no gold standard for the diagnosis of coronavi-
rus disease 2019 (COVID-19). The detection of SARS-CoV-2 by
nucleic acid amplification testing (NAAT) is largely done by real-
time RT-PCR on nose/throat swabs in centralized laboratories.Cell Reports
This is an open access article undRT-PCR specimens are often batch analyzed, and the turn-
around time for this test can be as long as 2–4 days in real-world
settings.2 NAAT tests from a single nose/throat swab are nega-
tive in up to 50% of patients who have computed tomography
(CT) changes consistent with COVID-19 and/or positive anti-
bodies to SARS-CoV-2.3–5 The lack of detectable virus in upper
airway samples is not only a serious barrier to making timely and
safe decisions in the emergency department but it also leads to
multiple swab samples being sent, frequently from the same
anatomical site, resulting in additional strain on virologyMedicine 1, 100099, September 22, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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fying infectious individuals. In addition, in severely ill patients,
tracheobronchial samples may be NAAT+, even when the
nose/throat swab is negative.4,6
Multiple factors may contribute to negative results by NAAT,
including test sensitivity, sampling technique, and timing of the
sampling in the disease course.6 The viral load in the upper res-
piratory tract is detectable from 4 days before symptoms7 and
frequently wanes after 1 week post-symptom onset.8,9 Similarly,
a case series from Germany found the detection rate by RT-PCR
was <50% after 5 days since onset of illness.10 A proportion of
patients develop secondary deterioration in clinical condition,
requiring hospitalization and respiratory support, at a time
when immune pathology rather than direct pathology related to
viral replication is thought to be dominant.9,11
An antibody response to SARS-CoV-2 is detectable 6 days
from infection and is almost always neutralizing.12,13 Antibody-
based diagnosis of COVID-19 shows increasing sensitivity in
the latter part of the infection course, when NAAT on nose/throat
samples is more likely to be negative.14–17 As a result, the diag-
nosis of infection and the identification of infectivity would
benefit from a combination of virologic and immunologic
markers to inform patient initial triage and subsequent manage-
ment. It is critical to determine whether a rapid point of care com-
bined antibody and nucleic acid testing strategy could improve
diagnosis.
We previously evaluated the diagnostic accuracy of the
SAMBA (simple amplification-based assay) II SARS-CoV-2 rapid
test compared with the standard laboratory RT-PCR and found
similar accuracy, with a turnaround time of 2–3 h, even in real-
world settings.18 Several studies have reported head-to-head
comparisons of immunochromatographic lateral flow immuno-
assays (LFAs).15–17,19 These assays are inexpensive tomanufac-
ture and provide a binary positive/negative result, thereby
lending themselves well to point-of-care (POC) testing. Even
though they have variable performance and in general are nega-
tive in the early phase of infection, they become highly sensitive
in the later stage of illness,15–17,19 and some are also highly
specific.
In this study, we evaluated the diagnostic performance of a
POC combination comprising NAAT and antibody testing
against a composite reference standard of laboratory RT-PCR
and a serum neutralization assay. Notably, SARS-CoV-2 viruses
with a D-to-Gmutation in Spike at position 614 have increased in
prevalence globally.20 Cryoelectron microscopy (cryo-EM)
studies suggest that D614 may play a role in Spike intermolec-
ular stability,21 potentially contributing to increased infectivity.20
Given that POC antibody tests were designed to detect anti-
bodies to the wild-type S protein, we also aimed to investigate
whether SARS-CoV-2 infections with D614G Spike mutant virus
could be diagnosed by POC antibody tests.
RESULTS
In phase one, 45 prospectively recruited participants in the COV-
IDx study with suspected COVID-19 disease had nose/throat
swabs specimens tested for nucleic acid and stored sera for
antibody testing. Samples at hospital admission were collected2 Cell Reports Medicine 1, 100099, September 22, 2020at a median of 7 (interquartile range [IQR] 7–13) days after illness
onset. The sera from 42.2% (19/45) participants showed neutral-
izing antibody response against SARS-CoV-2 Spike protein
pseudotyped virus infection in a neutralization assay using a cut-
off of 50% inhibition at 1:4 dilution (Figure 1A). The sera of 26 par-
ticipants showed no neutralizing response (Figure 1B). The
neutralization ability of participants’ sera was compared with
an in-house ELISA immunoglobulin G (IgG) assay for Spike-spe-
cific antibodies based on a recently reported method22 (Fig-
ure S1), and significant association between positive results in
both assays was demonstrated (Figure 1C, p < 0.0001). Figures
1D–1G show significant associations between the POC antibody
test result and both ELISA (p < 0.0001) and neutralization (p <
0.0025) assays. POC antibody testing showed no cross-reac-
tivity in sera obtained before the pandemic (Table S1). The
neutralization assay also demonstrated a lack of cross-reactivity
with SARS-CoV-1 on a limited subset of sera (Figure S2).
Results from the 4 IgG antibody assays used in this study were
confirmed (4 or 3 concordant) in 38/45 samples, and, against this
classification, neutralization (Figures 1A–1C), spike ELISA22 (Fig-
ures 1C, 1D, 1F, and S1), Surescreen, and COVIDIX Healthcare
assays gave a correct result in 100%, 97.4%, 92.1%, and
86.8% of cases, respectively, justifying the choice of the neutral-
ization assay as part of a composite reference standard.
A total of 53.3% (24/45) of participants hadCOVID-19 disease,
as determined by the composite reference standard (lab RT-
PCR and neutralization assay). The median age of the patients
was 73.5 (IQR 54.0–86.5) years in those with SARS-CoV-2 infec-
tion by our composite reference standard and 63.0 (IQR 41.0–
72.0) years in those without disease (Table 1). C-reactive protein
(CRP) and procalcitonin were significantly higher in confirmed
COVID-19 patients, and classical chest radiograph appearances
were more common in confirmed COVID-19 patients (Table 1,
p < 0.001). However, 6/24 (25%) had normal or indeterminate
chest radiographs in the confirmed COVID-19 group.
As expected from the clinical study inclusion criteria, >80% of
patients presented with influenza-like illness (ILI) with docu-
mented fever and 33% had clinical or radiological evidence
of pneumonia (Table 1). Highly experienced internal medicine
physicians were caring for suspected COVID-19 cases at our
institution, and this was partly due to the significant comorbid-
ities in the local population that mandated a broad differential
diagnostic approach in hospitalized individuals (Table 1). Among
the patients with COVID-19, one suffered from rheumatoid
arthritis and was immunosuppressed with prednisolone. Among
the patients without COVID-19, 5 were immunosuppressed for
the following conditions: psoriatic arthritis (usekinumab, anti-
interleukin-12 [IL-12], IL-23), multiple myeloma (lenalidomide
and dexamethasone), lymphoma (cyclosporin), hypersensitivity
pneumonitis (mycofenalate and prednisolone), and renal trans-
plant (mycofenalate and tacrolimus). No patients in the study
were under treatment with the anti-B cell monoclonal antibody
rituximab.
During the peak of the first wave, routine respiratory virus
testing was halted at our institution due to the demands of
SARS-CoV-2 testing and low seasonal prevalence of these
pathogens. Multiplex PCR for other respiratory viral pathogens
was performed in only 8 participants. Seven of these
Figure 1. Antibody Detection for SARS-CoV-
2: Cross-Validation of Lateral Flow Diagnostic
Tests (POC Antibody Tests) with ELISA and
SARS-CoV-2 Pseudotype Virus Neutralization
Assays
(A and B) Serum from COVID-19 suspected partici-
pants inhibited (n = 19) (A) or did not inhibit (n = 26) (B)
SARS-CoV-2 pseudotype virus infection in a
neutralization assay. Serum from a healthy donor
was used and a negative control. The error bars
represent SEMs.
(C) Comparison between ELISA and positive/nega-
tive results from neutralization assay; n = 37, p <
0.0001.
(D) Comparison between ELISA Spike protein reac-
tivity and positive/negative POC antibody test re-
sults (COVIDIX SARS-CoV-2 IgM/IgG test); n = 38,
p < 0.0001.
(E) Comparison between half-maximal effective
concentration (EC50) dilution titer from neutralizing
assay and positive/negative POC antibody test re-
sults (COVIDIX SARS-CoV-2 IgM/IgG test); n = 44,
p = 0.0025.
(F) Comparison between ELISA IgG and positive/
negative POC IgG band results for SureScreen
SARS-CoV-2 IgM/IgG test; n = 38, p < 0.0001.
(G) Comparison between EC50 dilution titer from
neutralization assay and positive/negative Sure-
Screen SARS-CoV-2 IgM/IgG antibody band test
results; n = 43, p = 0.005. The assays were per-
formed in duplicate.
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for influenza A.
The overall COVID-19 diagnosis rate (positive predictive
agreement) by rapid nucleic acid testing was 79.2% (95% confi-
dence interval [CI] 57.8–92.9), decreasing from 100% (95% CI
59.0%–100%) for days 1–4 to 50.0% (95% CI 11.8–88.2) for
days 9–28 post-symptom onset (Table 2; Figure S3). When
IgG/IgM rapid tests were combined with NAAT, the overall pos-
itive predictive agreement increased to 100% (95%CI 85.8–100)
(Table 2). Additional cases of COVID-19 detected in NAAT pa-
tients were identified by POC tests under investigation (Figure 2).
Among 21 COVID-19 individuals, there were 3 false positive re-
sults for 1 POC antibody test and 1 false positive result for theCell Reportsother, resulting in positive predictive values
of 88.9% and 96.0%, respectively, for
the 2 POC antibody/SAMBA II NAAT
combinations.
Those with positive NAAT and sequence
available were predominantly infected with
strains containing the D614G mutation in
Spike, downstream of the receptor-bind-
ing domain and located on the Spike sur-
face (Figures 3A and 3B). A total of 14/24
(58.3%) patients deemed to be COVID-
19+ by the reference composite standard
were positive by both rapid NAAT and
antibody testing, and 14/14 were infected
with strains bearing D614G, indicatingthat POC serological tests were able to detect infections with
this variant.
To understand the relationship between POC band intensity
and neutralization activity further, we identified 3 participants
(all infected with D614G Spike mutant) with stored samples at
multiple time points in their illness (Figure 4). Two individuals
were sampled from early after symptom onset, and the third pre-
sented 3weeks into illness. In the first two cases (Figures 4A–4F),
we observed an increase in neutralization activity over time that
was mirrored by band intensities on rapid POC antibody testing.
As expected, IgM bands arose early on, with IgG following
closely. Of note, in patient 1, there was a weakly detectable
IgM band by rapid test with no serum neutralization activityMedicine 1, 100099, September 22, 2020 3
Table 1. Characteristics of Participants in Diagnostic Accuracy
Study
COVID-19+ COVID-19
pan = 24 n = 21
Male sex (%) 14 (58.3) 9 (42.9) 0.30b
Median age,
y (IQR)
73.5 (54.0–86.5) 63.0 (41.0–72.0) 0.03
Influenza-like
illness with
documented fever
20 (83.3) 17 (81.0) 0.84
Clinical or
radiological evidence
of pneumonia
10 (41.7) 7 (33.3) 0.57
Immunosuppressed 0.053
Yes 1 (4.2) 5 (23.8) –
No 23 (95.8) 16 (76.2) –
Cardiovascular
disease
6 (25.0) 2 (9.5) 0.25
Chronic respiratory
disease
5 (20.8) 6 (28.6) 0.73
Chronic renal
disease
4 (16.7) 2 (9.5) 0.67
Diabetes mellitus 6 (25.0) 3 (14.3) 0.47
Median SpO2,
% (IQR)
95.0
(92.5–96.0)
96.0
(94.0–98.0)
0.09
Median FiO2,
% (IQR)
0.21
(0.21–0.24)
0.21
(0.21–0.21)
0.40
Median PaO2,
kPa (IQR)
5.0
(3.0–9.1)
7.2
(3.8–9.0)
0.30
Median PaO2:
FiO2 (IQR)
20.5
(13.3–32.9)
30.9
(18.1–36.2)
0.09
Median respiratory
rate, breaths/min
(IQR)
22.0
(19.0–27.5)
20.0
(17.0–23.0)
0.06
Median heart rate,
beats/min (IQR)
86.0
(77.5–99.5)
88.0
(78.0–107.0)
0.44
Median systolic BP,
mmHg (IQR)
139.5
(117.5–149.0)
135.0
(119.0–152.0)
0.90
Median duration
of illness, days (IQR)
7 (1–8) 10 (3–14) 0.10
Median Hb,
g/dL (IQR)
12.9
(12.0–13.8)
13.1
(11.6–14.1)
0.46
Median WCC, 3
109/L (IQR)
7.0
(5.0–8.0)
9.0
(7.0–14.0)
0.08
Median lymphocyte
count, 3109/L (IQR)
0.8
(0.5–1.2)
1.2
(0.8–1.5)
0.12
Median platelet
count, 3109/L (IQR)
213.5
(188.5–303.5)
271.0
(186.0–305.0)
0.59
Median ferritin,
mg/L (IQR)
684.7
(206.2–1059.1)
112.3
(49.6–323.6)
0.02
Median CRP,
mg/L (IQR)
72.0
(28.5–214.5)
12
(4.0–53.0)
0.004
Median procalcitonin,
ng/mL (IQR)
0.2
(0.1–0.6)
0.0
(0.0–0.1)
0.03
Table 1. Continued
COVID-19+ COVID-19
pan = 24 n = 21
Radiological findings <0.001b
Normal 2 (8.3) 9 (42.9) –
Indeterminate 4 (16.7) 3 (14.3) –
Classic 18 (75.0) 3 (14.3) –
Non-COVID 0 (0.0) 6 (28.5) –
COVID-19 status is based on composite reference standard test of nose/
throat swab SARS-CoV-2 RT-PCR + serum neutralization of pseudovi-
rus-bearing SARS-CoV-2 Spike. BP, blood pressure; Hb, hemoglobin;
WCC, white blood cell count.
aWilcoxon rank-sum test used except where indicated.
bChi-square test.
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OPEN ACCESS(Figures 4A and 4B). Over time, the band intensity for IgM and
IgG increased along with the serum neutralization activity. In
the individual presenting 21 days into illness (Figures 4G–4I),
only IgG was detected with rapid POC antibody testing, and,
as expected, the band intensity did not increase over the
following days.
In phase 2, we performed a prospective evaluation of com-
bined testing in 128 patients presenting with possible COVID-
19 from July 13 to 27, 2020. Their clinical presentation was
less severe and diagnoses broader than in phase 1 (Table 3),
with cardiovascular and gastrointestinal disease significantly
represented and respiratory disease representing just 60% of
cases—likely as a result of the increased appreciation of diverse
presentations of COVID-19 disease.23 Patients did have signifi-
cant comorbidities and 10% were immunosuppressed,
although without B cell-depleting agents (Table 3). By this
time, the POC NAAT test had been validated in a head-to-head
study against the lab RT-PCR and entered routine use,18 replac-
ing the RT-PCR. Given the need to further assess the specificity
of the POC antibody tests in routine clinical practice and with
fresh blood rather than serum, we compared the performance
of POC antibody tests on finger prick blood against serum
neutralization (Figures 5A and 5B).
In this second phase, there was only one NAAT positive pa-
tient, who was also positive by both POC antibody tests and
serum neutralization. There were three NAAT individuals pre-
senting with respiratory symptoms who had positive POC anti-
body tests by both COVIDIX and SureScreen, along with serum
neutralization activity. The POC antibody tests showed 100%
negative predictive agreement with serum neutralization and
the kappa correlation between POC antibody tests and serum
neutralization was extremely high, at 0.97.DISCUSSION
Here, we have shown that POCNAAT testing in combination with
antibody detection can significantly improve the diagnosis of
COVID-19. The overall positive predictive agreement against
the composite reference standard under clinical trial conditions
was79% for rapid NAAT testing of nose/throat swab samples,
reaching 100%with a combined approach of rapid NAAT testing
Table 2. Individual and Combined Diagnostic Accuracy of POC
Rapid NAAT-Based and Antibody Tests According to Time from
Initial Symptoms
% (95% CI)
Days 1–4 Days 5–8 Days 9–28 Overall
n = 14 n = 14 n = 17 N = 45a
SAMBA II NAAT
Positive
predictive
agreement
100
(59.0–
100)
81.8
(48.2–
97.8)
50.0
(11.8–
88.2)
79.2
(57.8–
92.9)
Negative
predictive
agreement
100
(59.0–
100)
100
(29.2–
100)
100
(71.5–
100))
100
(83.9–
100)
COVIDIX IgM and IgG
Positive
predictive
agreement
100
(59.0–
100)
90.9
(58.7–
99.8)
100
(54.1–
100)
95.8
(78.9–
99.9)
Negative
predictive
agreement
100
(59.0–
100)
66.7
(9.4–
99.2)
81.8
(48.2–
97.7)
85.7
(63.7–
97.0)
SAMBA II NAAT and COVIDIX IgM and IgG
Positive
predictive
agreement
100
(59.0–
100)
100
(71.5–
100)
100
(54.1–
100)
100
(85.8–
100)
Negative
predictive
agreement
100
(59.0–
100)
66.7
(9.4–
99.2)
81.8
(48.2–
97.7)
85.7
(63.7–
97.0)
SureScreen IgM and IgGa
Positive
predictive
agreement
42.9
(9.9–
81.6)
90.9
(58.7–
99.8)
100
(54.1–
100)
79.2
(57.8–
92.9)
Negative
predictive
agreement
100
(54.1–
100)
66.7
(9.4–
99.2)
100
(69.2–
100)
94.7
(74.0–
99.9)
SAMBA II NAAT and SureScreen IgM and IgGa
Positive
predictive
agreement
100
(59.0–
100)
100
(71.5–
100)
100
(54.1–
100)
100
(85.8–
100)
Negative
predictive
agreement
100
(54.1–
100)
66.7
(9.4–
99.2)
100
(69.2–
100)
94.7
(74.0–
99.9)
Positivity predictive agreement is the percentage of positive test results in
samples deemed positive by the composite reference standard. Negative
predictive agreement is the percentage of negative test results in sam-
ples deemed negative by the composite reference standard.
a43 of 45 patients had SureScreen antibody results.
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specificity of the combined approach was 85%–95% on stored
serum under clinical trial conditions and 100% on finger prick
blood in routine clinical care.
As expected, nucleic acid detection in nose/throat samples
was highest in those presenting within the first few days (100%
in samples taken in the first 4 days after symptom onset).
Conversely, antibody detection by LFA increased with time since
symptom onset, with 100% efficacy beyond the 9th day post-symptoms. One study reported that combined lab-based RT-
PCR with lab-based antibody testing could increase the sensi-
tivity for COVID-19 diagnosis from 67.1% to 99.4% in hospital-
ized patients.24 However, in that study, this assessment of sensi-
tivity was made using clinical diagnosis. A major strength of the
present study is the use of an objective reference standard that
included NAAT and serum neutralization, a phenotypic test for
the functionality of antibodies. This assay was shown to be
robust and accurate, using a recently described ELISA method
for SARS-CoV-2 IgG detection that is now used globally.22
The D614G Spike mutant has spread globally. Wild-type Spike
protein antigen is used in the development and validation of POC
antibody tests, including those tested here. Of critical importance
is the fact that both POC antibody tests (and ELISA) were able to
detect antibody responses in patients infected with the D614G
Spikemutant and that the band intensity of POC testing increased
with neutralization activity in these individuals. Given that POC
antibody tests are far cheaper and simpler to deploy, they will
likely be used in low-resource settings that do not have access
to NAAT.25 Demonstration that POC antibody LFA tests can
detect the D614G spike mutant is therefore of importance.
The use of antibody tests for COVID-19 diagnosis in hospitals
has been limited for a number of reasons. First, we know from
SARS-CoV-1 that previous humoral immunity to HCoV OC43
and 229E can elicit a cross-reactive antibody response to N of
SARS-CoV-1 in up to 14% of people tested in cross-sectional
studies,26 and previous exposure to HCoV can rarely elicit a
cross-reactive antibody response to the N and S proteins of
SARS-CoV-2.16,27 Second, antibody tests do not achieve the
same detection rates as nucleic acid-based tests early in infec-
tion, as humoral responses take time to develop following viral
antigenic stimulation. However, by day 6 post-symptom onset,
detection of IgG to Spike protein has been reported to reach
100%sensitivity,12 and this is useful in caseswith immune-medi-
ated inflammatory disease in which RT-PCR on respiratory sam-
ples is often negative—for example, in the recently described
Kawasaki-like syndrome called PIMS (pediatric inflammatory
multisystem syndrome).28
In phase one (COVIDx trial), we tested stored sera rather than
whole-blood finger prick, although this was intentional, given the
caution needed in interpreting LFAs and concern regarding po-
tential cross-reactivity of antibodies and poor specificity.
Although SARS-CoV-2 ELISA testing of our pre-pandemic sera
did reveal occasional N reactivity to SARS-CoV-2, likely due to
cross-reactivity with seasonal CoV, these samples were nega-
tive on POC antibody testing. However, the specificity of the
COVIDIX test was estimated at only 85%, compared to a more
acceptable 95% for SureScreen. We therefore carried out a pro-
spective evaluation of POC antibody testing on finger prick blood
in 128 suspected cases of COVID-19 to further evaluate the
specificity of both tests in routine clinical practice. We found
no false positives in patients whose sera were non-neutralizing.
This is consistent with an estimated specificity of >99% with
the SureScreen assay observed in an independent analysis us-
ing stored pre-pandemic sera.29 The greater incidence of false
positive POC antibody tests, predominantly with COVIDIX, on
stored sera as compared to fresh finger prick blood may be
due to processing and storage of sera, contamination of seraCell Reports Medicine 1, 100099, September 22, 2020 5
Figure 2. Venn Diagrams Comparing Positive
and Negative Diagnostic Test Results in Hospi-
talized Patients
Testing by NAAT and POC antibody testing by (A)
COVIDIX Healthcare IgM/IgG kit (n = 45) and (B)
SureScreen IgM/IgG kit (n = 43).
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tors that differed between the two phases. Nevertheless, now
that we are in a low incidence period, it is advisable to perform
confirmation testing using an alternative platform for either a sin-
gle positive antibody or NAAT test, as is now the policy at our
institution. One should note in particular that antibody tests
may be negative in patients with immunosuppression, high-6 Cell Reports Medicine 1, 100099, September 22, 2020lighting that patient factors can influence
the interpretation of results and that alterna-
tive diagnoses should be considered.
We envisage a deployment approach
whereby both test samples, finger prickwhole blood and nose/throat swab, are taken at the same time
on admission to the hospital. The finger prick antibody test result
is available within 15 min. Due to the possibility of false positive
results from POC serology testing, a positive POC antibody test
result as the only positive marker should ideally be confirmed
with a second rapid POC test/laboratory IgG/IgM test before
movement to a COVID-19 area or recruitment into a clinicalFigure 3. Spike D614G Characterization in
the Phase 1 Clinical Cohort (A) Genome
map of SARS-CoV-2, with overall topog-
raphy of Spike expanded. FP, fusion peptide;
HR1, heptad repeat 1; HR2, heptad repeat 2;
IC, intracellular domain; NTD, N-terminal
domain; RBD, receptor-binding domain;
TM, transmembrane region. The aligned
sequence of 10 amino acids on either side
of D614 is shown for 16 participants for
whom sequence data were available. A dot
represents where the amino acid is un-
changed from wild type, the mutant glycine
is represented by G.
(B) Top view of SARS-CoV-2 Spike glycoprotein
trimeric structure in a closed state, with position
614 in yellow in each protomer. Structure deter-
mined by cryoelectron microscopy. RCSB PDB:
6VXX.
Figure 4. Longitudinal Antibody Responses in Patients Infected with D614G Mutant SARS-CoV-2 Detected by Rapid Lateral Flow and
Neutralization Assays
(A, D, and G) An immunochromatographic lateral flow rapid diagnostic test (POC antibody test-COVIDIX SARS-CoV-2 IgM IgG test) on longitudinal samples in
individual patients detecting SARS-CoV-2 IgM and IgG bands. Band intensities were acquired using the ChemiDoc MP Imaging System and quantified using
Image Lab software.
(B, E, and H) SARS-CoV-2 pseudotyped virus neutralization assay from longitudinal serum samples in individual patient examples. The assays were performed in
duplicate. The error bars represent SEMs.
(C, F, and I) Comparison of IgG band intensities from lateral flow rapid diagnostic test with EC50 neutralization titers from SARS-CoV-2 pseudotyped virus
neutralization assay in individual patients. The correlations were estimated by linear regression analysis.
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Figure 5. Distribution of Serum Neutralization Activity against
SARS-CoV-2 in Hospitalized Patients during the Implementation
Phase
(A) Neutralization EC50 dilution titer interpreted as positive or negative using a
cutoff for positive neutralization of 1:4 dilution.
(B) Neutralization data for individual patients stratified by POC antibody test
result (both tests were fully concordant in phase 2). The data points represent
the reciprocal dilution of serum required to inhibit 50% of infection by lentivirus
pseudotyped with the SARS-CoV-2 Spike glycoprotein. The assays were
performed in duplicate. The line represents the mean and the bar represents
the standard deviation (n = 101 sera tested).
Table 3. Characteristics of 128 Individuals Hospitalized with
Suspected COVID-19 during Implementation of Combined POC
Testing
Characteristic n
Male gender (%) 42.2
Median age, y (IQR) 67 (50.8–80.0)
Median SpO2, % (IQR) 96 (95–97)
Median fiO2 (IQR) 0.21 (0.21–0.21)
Maximal additional ventilatory support
Nasal cannulae 24
Face mask 7
LTOT/NIV 4
Intubation 1
Median duration of illness, days (IQR) 2.5 (1–7)
NAAT+ (%) 2 (1.6)
Neutralization positive (%, n = 101) 8 (7.9)
COVIDIX Healthcare IgG/M+ (%)a 6 (3.9)
SureScreen IgG/M+ (%)a 6 (3.1)
Median lymphocyte count, 3109/L (IQR) 1.3 (0.76–1.76)
Median CRP, mg/L (IQR) 46 (15–129)
Comorbidities
Cardiovascular disease 44 (34.3)
Chronic respiratory disease 62 (48.4)
Chronic kidney disease 11 (8.6)
Diabetes mellitus 24 (18.8)
Immune suppression 13 (10.2)
Diagnosis
Respiratory 61
Cardiovascular 16
Gastrointestinal 13
Genitourinary 7
Other 30
NEWS score 2 (1–5)
Chest radiograph findings (n = 114)
Normal 59
Indeterminate 31
Classic 0
Non-COVID-19 24
CT findings (n = 24)
Normal 3
Indeterminate 7
Classic 1
Non-COVID-19 13
LTOT, long-term oxygen therapy; NAAT, nucleic acid amplification testing;
NEWS; national early warning score; NIV, non-invasive ventilation.
aTesting done on stored serum due to finger prick test failure.
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from chest imaging and blood tests such as lymphocyte count
and CRP are considered in clinical decision making when as-
sessing patinets for COVID-19. Further swabs for NAAT testing
are also taken where possible.8 Cell Reports Medicine 1, 100099, September 22, 2020A confirmed positive NAAT result remains critical not only to
identify early infection but, more important, to triage infectious
patients to be isolated from other patients and be handled with
particular care by staff. NAAT is also valuable in milder and
asymptomatic cases, given that severity appears to correlate
with the magnitude of antibody responses.16,30
In conclusion, rapid combined testing could be important in
the diagnosis and management of COVID-19, particularly given
that the pandemic is not well controlled in many parts of the
world and as diverse manifestations of disease emerge.Limitations of Study
This study was limited by the fact that it was conducted at a sin-
gle center with relatively small numbers of individuals in the clin-
ical study (phase 1), largely due to a lack of available stored
serum. Phase 1 of the study used stored serum, in which there
was a higher false positive rate than phase 2, in which whole
bloodwas used. The implementation study (phase 2) had greater
numbers and was able to effectively demonstrate the high spec-
ificity and the very low false positive rate of the POC antibody
tests on whole blood. However, it was hampered by the low inci-
dence of COVID-19 infection during the period it was under-
taken. This limited the further evaluation of the sensitivity of the
combined approach. There was also a lack of data on repeated
sampling and sampling from deeper respiratory sites in those
suspected cases who were NAAT. Future larger studies are
warranted.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Clinical Study
The study was conducted in two phases; a clinical validation phase followed by an implementation phase. The study participants in
phase onewere part of theCOVIDx trial,18 a prospective analytical studywhich compared SAMBA II SARS-CoV-2 point of care test to
the standard laboratory RT-PCR test for the detection of SARS-CoV-2 in participants admitted to Cambridge University Hospitals
NHS Foundation Trust (CUH) with a possible diagnosis of COVID-19. Consecutive participants were recruited during 12-hour day
shifts over a duration of 4 weeks from the 6th of April 2020 to the 2nd of May 2020. We recruited adults (> 16 years old) presenting
to the emergency department or acute medical assessment unit as a possible case of COVID-19 infection. This included any adult
requiring hospital admission andwhowas symptomatic of SARS-CoV-2 infection, demonstrated by clinical or radiological findings.18
45 participants who had available stored sera were included in this sub-study and underwent further antibody testing. Phase 2, from
July 13th to 27th 2020, comprised a service evaluation of clinical practice whereby adults (> 16 years old) presenting to the emergency
department or acute medical assessment unit as a possible case of COVID-19 infection were included. This included any adult
requiring hospital admission and who was symptomatic of SARS-CoV-2 infection, demonstrated by clinical or radiological findings.
Cell lines
293T cells were cultured in DMEM complete (DMEM supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS)
and maintained at 37C in %% CO2.
Ethical approval
COVIDx (NCT04326387) was approved by the East of England - Essex Research Ethics Committee (REC ref: 20/EE/0109). Serum
samples were obtained from patients attending Addenbrooke’s Hospital with a suspected or confirmed diagnosis of COVID19. Pro-
spective combined point of care testing of suspected COVID-19 cases was done under CUH NHS Trust service evaluation 3163.
METHOD DETAILS
Test methods
NAAT tests
The standard laboratory RT- PCR test, developed by public health England (PHE), targeting the RdRp genewas performed on a com-
bined nose/throat swab. This test has an estimated limit of detection of 320 copies/ml. In parallel, SAMBA II SARS-CoV-2 testing was
performed on a combined nose/throat swab and inactivated in a proprietary buffer at the point of sampling. SAMBA II SARS-CoV-2
targets 2 genes- Orf1 and the N genes and uses nucleic acid sequence based amplification to detect SARS-CoV-2 RNA, with limit of
detection of 250 copies/ml.31
Pseudotype virus preparation
Viral vectors were prepared by transfection of 293T cells by using Fugene HD transfection reagent (Promega) as follows. Confluent
293T cells were transfected with a mixture of 11ul of Fugene HD, 1mg of pCAGGS_SARS-CoV-2_Spike or pCDNAD19Spike-HA, 1ug
of p8.91 HIV-1 gag-pol expression vector,32,33 and 1.5mg of pCSFLW (expressing the firefly luciferase reporter gene with the HIV-1
packaging signal). Viral supernatant was collected at 48 and 72h after transfection, filtered through 0.45um filter and stored at80C.
The 50% tissue culture infectious dose (TCID50) of SARS-CoV-2 pseudovirus was determined using Steady-Glo Luciferase assay
system (Promega).
Pseudotype neutralisation assay
Spike pseudotype assays have been shown to have similar characteristics as neutralisation testing using fully infectious wild-type
SARS-CoV-2.34 Virus neutralisation assays were performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using
SARS-CoV-2 Spike pseudotyped virus expressing luciferase. Pseudovirus was incubated with serial dilution of heat inactivated hu-
man serum samples from COVID-19 suspected individuals in duplicates for 1h at 37C. Virus and cell only controls were also
included. Then, freshly trypsinized 293T ACE2/TMPRSS2 expressing cells were added to each well. Following 48h incubation in a
5% CO2 environment at 37
C, the luminescence was measured using Steady-Glo Luciferase assay system (Promega).
Enzyme-linked immunosorbent assay (ELISA)
We developed an ELISA targeting the SARS-CoV-2 Spike and N proteins. Trimeric spike protein antigen used in the ELISA assays
consists of the complete S protein ectodomain with a C-terminal extension containing a TEV protease cleavage site, a T4 trimeriza-
tion foldon and a hexa-histidine tag. The S1/S2 cleavage site with amino acid sequence PRRAR was replaced with a single Arginine
residue and stabilizing Proline mutants were inserted at positions 986 and 987. Spike protein was expressed and purified from
Expi293 cells (Thermo Fisher). N protein consisting of residues 45-365 was initially expressed as a His-TEV-SUMO-fusion. After
Ni-NTA purification, the tag was removed by TEV proteolysis and the cleaved tagless protein further purified on Heparin and gel filtra-
tion columns.e2 Cell Reports Medicine 1, 100099, September 22, 2020
Report
ll
OPEN ACCESSThe ELISAs were in a stepwise process; a positivity screen was followed by endpoint titer as previously described.22 Briefly, 96-
well EIA/RIA plates (Corning, Sigma) were coated with PBS or 0.1 mg per well of antigen at 4C overnight. Coating solution was
removed, and wells were blocked with 3% skimmed milk prepared in PBS with 0.1% Tween 20 (PBST) at ambient temperature
for 1 hour. Previously inactivated serum samples (56C for 1 hour) were diluted to 1:60 or serially diluted by 3-fold, six times in
1% skimmed milk in PBST. Blocking solution was aspirated and the diluted sera were added to the plates and incubated for 2 hours
at ambient temperature. Diluted sera were removed, and plates were washed three times with PBST. Goat anti-human IgG second-
ary antibody-Peroxidase (Fc-specific, Sigma) prepared at 1:3,000 in PBST was added and plates were incubated for 1 hour at
ambient temperature. Plates were washed three times with PBST. ELISAs were developed using 3,5,30,50- tetramethylbenzidine
(TMB, ThermoScientific); reactions were stopped after 10 minutes using 0.16M Sulfuric acid.
COVIDIX 2019 SARS-CoV-2 IgG/IgM Test (COVIDIX Healthcare, Cambridge, UK)
This colloidal-gold lateral flow immunoassay is designed to detect IgG and IgM to SARS-CoV-2. The test is CE marked. It was used
according to the manufacturer’s instructions. 10ml of serum was added to the test well followed by 2 drops of the manufacturer’s
proprietary buffer. In order to rule out cross reactivity of this test with seasonal coronavirus antibodies we tested 19 stored specimens
from before 2020, some of which had N and S protein SARS-CoV-2 cross reactivity (Table S2).
SureScreen SARS-CoV-2 IgG/IgM Test (SureScreen Diagnostics Ltd, Derby, UK)
This colloidal-gold lateral flow immunoassay is designed to detect IgG and IgM to SARS-CoV-2. It was used according to the man-
ufacturer’s instructions. The test has been CE marked and previously validated against a large panel of negative historical controls
and in serum from confirmed PCR positive COVID-19 cases.16 10ml of serum was added to the test well followed by 2 drops of the
manufacturer’s proprietary buffer.
Next generation sequencing of SARS-CoV-2 isolates in nose/throat swabs
Samples with CT values above 33 were sequenced with a multiplex PCR approach according to the ARTIC version 2 protocol with
version 3 primer set. Amplicons were sequenced usingMinION flow cells version 9.4.1 (Oxford Nanopore Technologies, Oxford, UK).
Genomes were assembled as previously described.35 The sequences are freely available from GISAID EpiCoVTM under accession
IDs: EPI_ISL 433757, 433754, 433792, 433850, 433751, 433778, 433869, 433875, 433874, 433917, 433962, 433956, 434034,
438681, 438711 and 444331. The submitting laboratory is the COVID-19 Genomics UK (COG-UK) Consortium and the originating
laboratory is Department of Pathology, University of Cambridge.
QUANTIFICATION AND STATISTICAL ANALYSIS
Enzyme-linked immunosorbent assay (ELISA) quantification
The optical density at 450 nm (OD450) was measured using a Spectramax i3 plate reader. The absorbance values for each sample
were determined by subtracting OD values from uncoated wells. All data analyses were performed using Prism 8 version 8.4.2
(GraphPad). An OD cut off of 0.3 was used to define a positive IgG response to full length Spike protein.
COVIDIX 2019 nCoV IgG/IgM Test band density
For quantification of IgG and IgM band density in COVIDIX 2019 nCoV IgG/IgM Test, high resolution images of completed POC anti-
body test cassettes were acquired using ChemiDocMP Imaging System (Bio-Rad) at 20min post-addition of the human serum. Band
intensities were analyzed using Image Lab software (Bio-Rad).
Quantification of neutralisation sensitivity
The 50% inhibitory dilution (EC50) was defined as the serum dilution at which the relative light units (RLUs) were reduced by 50%
compared with the virus control wells (virus + cells) after subtraction of the background RLUs in the control groups with cells
only. The EC50 values were calculated with non-linear regression, log (inhibitor) versus normalized response using GraphPad Prism
8 (GraphPad Software, Inc., San Diego, CA, USA). The neutralisation assay was positive if the serum achieved at least 50% inhibition
at 1 in 3 dilution of the SARS-CoV-2 spike protein pseudotyped virus in the neutralisation assay. The neutralisation result was nega-
tive if it failed to achieve 50% inhibition at 1 in 3 dilution.
Assessment of neutralisation assay performance
Four assays detecting IgG to COVID-19 were utilized in this study. 38 of the 45 samples were identified as concordant with at least
three of the four assays and considered confirmed either negative or positive. Against this group of samples validated for content of
COVID-19 IgG, each individual assay was assessed. Neutralisation, ELISA, SureScreen and COVIDIX assays gave a correct result in
100%, 97.4%, 92.1% and 86.8%, respectively, justifying the choice of the neutralisation assay as standard.
Analyses
The performance of SAMBA II SARS-CoV-2 test and COVIDIX SARS-CoV-2 IgG/IgM Test or SureScreen SARS-CoV-2 IgG/IgM Test
for diagnosing COVID-19 were calculated alone and then in combination along with binomial 95% confidence intervals (CI). A
composite reference standard was used - standard lab RT-PCR and a neutralisation assay. Descriptive analyses of clinical andCell Reports Medicine 1, 100099, September 22, 2020 e3
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when categorical. The differences in continuous and categorical data were tested using Wilcoxon rank sum and Chi-square test
respectively. Statistical analysis were conducted using Stata (version 13) and GraphPad Prism (version 8), with additional plots
generated using GraphPad Prism. Venn diagrams were prepared using Venny.36 Structural modeling of location of D614G was
done using Mol*.38
ADDITIONAL RESOURCES
COVIDx was registered with the ClinicalTrials.gov Identifier NCT04326387.e4 Cell Reports Medicine 1, 100099, September 22, 2020
